18889881171
Kalkine 0
countryflagUS

Bavarian Nordic A/S ADR

Healthcare US BVNRY

9.23USD
-0.22(2.33%)

Last update at 2025-07-14T13:30:00Z

Day Range

9.239.23
LowHigh

52 Week Range

6.8614.60
LowHigh

Fundamentals

  • Previous Close 9.45
  • Market Cap2169.38M
  • Volume100
  • P/E Ratio13.34
  • Dividend Yield-%
  • EBITDA1955.44M
  • Revenue TTM6082.63M
  • Revenue Per Share TTM30.66
  • Gross Profit TTM 1701.26M
  • Diluted EPS TTM0.69

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -331.61100M -454.43000M 281.98M -344.74900M -356.63500M
Minority interest - - - - 0.00000M
Net income -347.38200M -464.77500M 277.52M -346.77700M -361.92700M
Selling general administrative 376.02M 292.92M 278.14M 173.42M 179.96M
Selling and marketing expenses 212.93M 191.78M 285.78M 53.48M 33.73M
Gross profit 1701.26M 570.32M 657.29M 307.73M 245.50M
Reconciled depreciation 399.25M 388.31M 360.15M 57.05M 41.64M
Ebit -3.84500M -263.31400M 449.62M -316.43200M -319.50900M
Ebitda 395.40M 125.00M 809.77M -259.38700M -277.87000M
Depreciation and amortization 399.25M 388.31M 360.15M 57.05M 41.64M
Non operating income net other - - - - 0.00000M
Operating income -3.84500M -263.31400M 449.62M -316.43200M -354.48200M
Other operating expenses 3221.58M 2211.42M 1472.80M 990.93M 855.10M
Interest expense 119.69M 152.06M 177.00M 18.49M 14.53M
Tax provision 15.77M 10.35M 4.46M 2.03M 5.29M
Interest income 0.03M 1.74M 0.19M 0.60M 0.84M
Net interest income -65.27300M -118.13600M -100.33400M -1.45300M 8.08M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense 15.77M 10.35M 4.46M 2.03M 5.29M
Total revenue 3150.79M 1897.88M 1852.38M 662.49M 500.62M
Total operating expenses 1772.05M 883.86M 277.70M 636.18M 599.98M
Cost of revenue 1449.53M 1327.56M 1195.09M 354.76M 255.12M
Total other income expense net -327.76600M -191.11600M -167.64800M -28.31700M -2.15300M
Discontinued operations - - - - 0.00000M
Net income from continuing ops -347.38200M -464.77500M 277.52M -346.77700M -361.92700M
Net income applicable to common shares -347.38200M -464.77500M 277.52M -346.77700M -361.92700M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 14353.21M 12391.25M 12089.27M 8759.06M 7047.07M
Intangible assets 6481.74M 5942.64M 5803.96M 5290.75M 5484.26M
Earning assets - - - - -
Other current assets 113.73M 720.34M 556.98M 190.36M 81.75M
Total liab 4013.28M 5241.26M 4714.60M 3864.71M 5181.61M
Total stockholder equity 10339.93M 7149.99M 7374.67M 4894.35M 1865.45M
Deferred long term liab - - - - -
Other current liab 1779.98M 551.34M 23.92M 4.85M 1.14M
Common stock 780.98M 707.35M 704.68M 584.50M 323.89M
Capital stock 780.98M 707.35M 704.68M 584.50M 323.89M
Retained earnings 9330.00M 6300.57M 6588.91M 4246.36M 1460.01M
Other liab - 2891.08M 2729.60M 2464.93M 2691.40M
Good will - - - - -
Other assets - 212.62M 43.16M 4.12M 1.45M
Cash 1477.23M 575.41M 591.82M 285.49M 297.55M
Cash and equivalents - - - - -
Total current liabilities 2787.87M 2287.34M 1908.56M 952.31M 2047.22M
Current deferred revenue 7.21M - 725.39M 579.54M 545.03M
Net debt -1331.93200M 1183.92M 540.77M 184.58M 1534.41M
Short term debt 46.55M 1130.07M 895.64M 22.60M 1388.97M
Short long term debt 1.91M 1105.58M 874.37M 2.17M 1375.12M
Short long term debt total 145.30M 1759.33M 1132.59M 470.06M 1831.96M
Other stockholder equity 228.95M 142.06M 81.08M 63.49M 81.56M
Property plant equipment - 1751.41M 1488.51M 1083.14M 906.49M
Total current assets 5403.05M 4484.58M 4753.64M 2381.05M 654.87M
Long term investments - - - - 1.45M
Net tangible assets - 1207.35M 1570.71M -396.39900M -3618.80000M
Short term investments 390.25M 2269.76M 3124.80M 1384.12M 174.82M
Net receivables 1778.10M 523.14M 447.95M 176.02M 69.03M
Long term debt 15.13M 583.43M 179.41M 393.27M 395.44M
Inventory 1643.74M 919.07M 480.04M 521.08M 100.76M
Accounts payable 954.14M 605.93M 263.61M 345.32M 112.09M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 230.49M - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 15.74M 212.62M 43.16M 4.12M 1.45M
Deferred long term asset charges - - - - -
Non current assets total 8950.16M 7906.67M 7335.63M 6378.02M 6392.19M
Capital lease obligations 128.25M 70.32M 78.81M 74.62M 61.40M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -877.40500M -1779.45400M -1202.14500M 1861.14M 229.21M
Change to liabilities 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total cashflows from investing activities -877.40500M -2876.94600M -1911.53200M -809.94000M 17.09M
Net borrowings 607.34M 638.32M -1393.39700M 1111.15M 244.58M
Total cash from financing activities 635.82M 3536.08M 1334.87M 1114.67M 245.84M
Change to operating activities 423.41M -146.00700M 345.72M -51.22900M -10.97300M
Net income -347.38200M -464.77500M 277.52M -346.77700M -361.92700M
Change in cash -16.41300M 306.33M -12.05800M 30.89M -15.86300M
Begin period cash flow 591.82M 285.49M 297.55M 266.66M 282.52M
End period cash flow 575.41M 591.82M 285.49M 297.55M 266.66M
Total cash from operating activities 220.05M -358.50000M 571.91M -275.91000M -288.52900M
Issuance of capital stock 37.92M 2963.78M 2842.55M 10.31M 5.42M
Depreciation 399.25M 388.31M 360.15M 57.05M 41.64M
Other cashflows from investing activities -169.46000M -39.04100M -2.67700M -0.07300M -0.15600M
Dividends paid - - - - 0.00000M
Change to inventory -439.02900M 41.04M -420.32000M -22.07400M 33.16M
Change to account receivables -133.16700M -364.39300M -88.09400M 15.76M -39.99000M
Sale purchase of stock -9.32800M -8.58100M -11.09900M -4.57600M -4.12400M
Other cashflows from financing activities 981.57M 583.05M -120.98300M 1357.81M 246.70M
Change to netincome 318.15M 193.20M 116.15M 71.36M 49.56M
Capital expenditures 1381.58M 1058.45M 706.71M 2671.01M 211.96M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital -148.78900M -469.36100M -162.69100M -57.54000M -17.80400M
Stock based compensation 49.28M 56.86M 33.00M 26.45M 33.91M
Other non cash items 267.69M 140.88M 97.61M 38.50M 2.15M
Free cash flow -1161.52200M -1416.95100M -134.79900M -2946.92000M -500.49000M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BVNRY
Bavarian Nordic A/S ADR		 -0.22 2.33% 9.23 13.34 4.99 2.47 1.42 2.24 10.75
NVO
Novo Nordisk A/S		 0.27 0.39% 69.20 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.49 0.70% 70.49 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.04 0.86% 472.89 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 4.77 0.84% 572.51 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Bavarian Nordic A/S ADR

Philip Heymans Alle 3, Hellerup, Denmark, 2900

Key Executives

Name Title Year Born
Dr. Paul John Chaplin MSc, Ph.D. CEO & Pres 1967
Mr. Henrik Juuel M.Sc. CFO & Exec. VP 1965
Mr. Russell Thirsk Exec. VP & COO NA
Mr. Rolf Sass Sørensen VP of Investor Relations & Communications NA
Ms. Anu Helena Kerns Exec. VP & Chief People Officer 1972
Mr. Jean-Christophe May Exec. VP & Chief Commercial Officer 1967
Dr. Laurence De Moerlooze Exec. VP & Chief Medical Officer 1964
Dr. Paul John Chaplin MSc, Ph.D. CEO & President 1967
Mr. Henrik Juuel M.Sc. CFO & Executive VP 1965
Mr. Russell Thirsk M.Sc. Executive VP & COO 1968

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.